This site is intended for healthcare professionals
News

EU approves Akynzeo IV formulation for treating nausea.- Helsinn

Read time: 1 mins
Published:24th Mar 2020
Helsinn announced that the European Commission (EC) has approved the intravenous formulation of Akynzeo (fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for preventing CINV. The European approval follows a positive opinion by the Committee for Medicinal Products for Human Use (CHMP), in December 2019. Helsinn submitted its MAA to the EMA for Akynzeo IV in November 2018, as a line extension of oral Akynzeo. Akynzeo hard capsules was previously approved by the European Commission as a fixed dose combination in 2015 for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin?based cancer chemotherapy and moderately emetogenic cancer chemotherapy.Comment: Akynzeo (oral and IV) is indicated in the EU for adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy.
Condition: Nausea
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.